Colon Cancer and Colorectal Cancer Treatment Options with Powerful
Combinations Designed for a Holistic Recovery
Living a long, healthy, and cancer-free life is possible, despite facing a late-stage or metastatic colon cancer
diagnosis. At Envita Medical Centers, a world-class integrative center for Precision Oncology, we have been treating
complex and late-stage cancers for over 25 years by combining the best in conventional medicine with advanced natural
therapies. The goal of team Envita is to pursue lasting progress in the fight against colorectal cancer, a term used
to define cancers of the colon and rectum regions, and survivors like Sandy Y. bear testimony to our relentless
endeavors.
Disclaimer: Individual results will vary. Envita makes no guarantees for outcomes. Each patient case is unique. Please
consult your doctor before making any changes to your medical treatment. Not every patient is a candidate for care or
achieves these results. Treatments used in this case may not all be FDA approved for the treatment of this condition.
Most cancer hospitals in the country follow the NCCN (National Comprehensive Cancer Network) guidelines, which does
not
give them the liberty to deviate much from a set protocol and personalize treatment based on each patient’s unique
biomarkers. Biomarkers refer to the proteins, genes, and other molecules which affect your distinctive colon cancer’s
growth and metastatic spread. This constraint in the one-size-fits-all regimens deprive patients of a true second
opinion, which Sandy finally received at Envita, and feels fortunate about getting treated in time for her aggressive
stage IV colon cancer.
Sandy came to us 25 years ago with Metastatic Colon
Cancer,
after facing bleak prognoses from some of the renowned
cancer hospitals in the nation.
Disclaimer: Individual results will vary. Envita makes no guarantees for outcomes. Each patient case is unique. Please
consult your doctor before making any changes to your medical treatment. Not every patient is a candidate for care or
achieves these results. Treatments used in this case may not all be FDA approved for the treatment of this condition.
According to
the American Cancer Society, which relies on data compiled and maintained by the National Cancer Institute
(NCI), the 5-year relative survival rate for colon cancer is a dismal
14% when the disease has metastasized to
distant
parts of the body.
However, Sandy has defied these statistics with our unique cancer care approach, and her enthusiasm in sharing her
journey from being a colon cancer patient to cancer-free for decades speaks volumes about our powerful combinations of
leading edge conventional and advanced natural therapies. The medical technology we provide at Envita today is light
years ahead of what we could offer Sandy 25 years ago, which proves our dedication towards innovating in the field of
personalized precision oncology to help every patient overcome their disease.
How Does Personalized Precision Oncology Help in Your
Holistic
Recovery?
Personalized precision oncology goes beyond the standardized treatment of colon cancer to identify, the
drivers of
genomic alterations, biomarkers, and immune dysfunction. All these causative factors are unique to each
individual
colon cancer patient, which is why a personalized approach is needed to address and treat the root cause of
each
individual patient’s unique cancer.
Personalization to Tackle Colorectal Cancer Recurrence
Our customized treatment plans are aimed at precision-targeting the distinctive colon (colorectal) cancer expressions
of
each patient to give them the best chance to respond to care. At Envita, we excel in personalizing each colorectal
cancer patient’s treatments with the latest medical innovations while rebuilding their immune system, which is
essential
for a long-term remission, unhindered by recurrences.
Disclaimer: Individual results will vary. Envita makes no guarantees for outcomes. Each patient case is unique. Please
consult your doctor before making any changes to your medical treatment. Not every patient is a candidate for care or
achieves these results. Treatments used in this case may not all be FDA approved for the treatment of this condition.
At Envita, we understand the importance of going beyond stipulated NCCN guidelines to chart a unique medical
blueprint,
which may help in overcoming the challenges of recurrence and metastases. The following are some of the hurdles in
colorectal cancer treatments, which we aim to overcome with our custom-developed advanced precision oncology
protocols:
The standard NCCN guided treatments based on cancer type and stage may not be enough to check recurrence, which is
one
of the most important factors influencing survival of colorectal cancer patients [1].
According to recent medical research, colorectal cancer can spread very soon after the original polyp or tumor has
developed, maybe years before the disease is diagnosed [2].
With standard chemotherapy the 5-year relative survival rate of metastatic colon cancer is as low as 10 percent
[3].
At Envita, we understand the importance of going beyond stipulated NCCN guidelines to chart a unique medical
blueprint,
which may help in overcoming the challenges of recurrence and metastases.
What is Metastatic Colorectal Cancer?
Metastasis refers to the spread of cancer beyond its primary site of origin. For instance, a cancer originating
in the
colon or the rectum, can spread or metastasize to the nearby lymph nodes and gradually affect distant regions
such as
the lungs, liver, brain, or bones.
Metastasis from the primary site of cancer can begin even when the polyp or tumor size is as small
as 2mm in diameter,
often the size seen in early stage II or stage I fully contained tumors. Tiny micro-metastatic cancer cells
break away
from a growing tumor and travel through blood vessels, seeding the disease at different regions or organs.
At Envita, we have several proprietary treatments beyond standard healthcare options like
radiofrequency
ablations and
hepatic arterial infusions to address liver metastases or other sites of colorectal cancer spread, such as
lungs, bones,
or any other organs.
Physicians with MD, NMD, DO, DO(h), MD(h), medical licenses
22
Pharmacists specializing in integrative agents
7
Nurses trained in precision treatment delivery
40+
Envita’s Precision Oncology May Improve Outcomes and Save Lives
At Envita, we see many patients with cancer recurrence or metastasis, despite receiving standard NCCN guideline
treatments and participating in clinical trials. In our clinical opinion, the lack of personalization to genetically
target each patient’s unique cancer expressions, in both these treatment approaches leads to advanced colon cancer
that
metastasizes to different parts of the body.
The one-size-fits-all NCCN guidelines are based on clinical trial data, ignoring each patient’s individual cancer
expressions, which is why not all patients with the same stage and type of colon cancer respond similarly to the same
treatment. These guidelines don’t allow access to precision oncology, until patients fail initial first-line
treatments
based on cancer type and stage. The delay in access to precision care may turn catastrophic for certain patients.
On the contrary, every
patient at Envita begins treatment with our uniquely detailed Precision Oncology Algorithms.
Less than 20% of all cancer patients get access to precision oncology [4] and even when they do, they get a
watered-down
version of Envita’s detailed precision algorithms. Our level of precision is much more in-depth, and includes testing
of
several other parameters, which play a direct or indirect role in cancer growth, recurrence, and metastasis.
Envita’s Precision
Algorithm identifies each patient’s unique Colorectal Cancer drivers, paving the way to longer
disease-free survival!
Envita Precision Algorithm vs. Standard Oncology Precision Testing
Envita Medical Centers
Standard Oncology Precision Testing
RNA Transcriptome Genes
Envita Medical Centers:20,000+
Standard Oncology:Unchecked
SNV/CNV Genes
Envita Medical Centers:452
Standard Oncology:309
Rearrangements/Fusion Genes
Envita Medical Centers:51
Standard Oncology:27
Microsatellite Instability (MSI)
Envita Medical Centers:Checked
Standard Oncology:Checked
Tumor Mutation Burden (TMB)
Envita Medical Centers:Checked
Standard Oncology:Checked
BRCA 1/2
Envita Medical Centers:Checked
Standard Oncology:Checked
Immunohistochemistry
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Chemosensitivity
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Concurrent Liquid Biopsy
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Exosomal miRNA Analysis
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Circulating Tumor Cells Enumeration
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Pharmacogenomics
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Individualized Therapy Recommendation
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Carcinogenic Exposure - Root Causes
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Inflammation Markers
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Metabolic Target Drivers
Envita Medical Centers:Checked
Standard Oncology:Unchecked
*Individual results may vary. Envita
makes no guarantees for outcomes.
Envita’s detailed precision algorithm offers a better understanding of the unique ecosystem of each patient’s
distinctive cancer, which is crucial to customize treatment for reducing chances of drug resistance. Chemotherapeutic
drug resistance is a challenge in cancer treatment because it may render treatment ineffective, causing disease
complications and metastasis. Given that the drug resistance mechanisms are different among colon cancer patients and
may change even in a single patient at different stages, personalized and specific combination therapy is proposed to
be
more effective and safer for the reversal of drug resistance [5], which is what we follow here at Envita, leading to
numerous successful recoveries like Sandy.
Unique and Advanced Treatments for Colon Cancer and Colorectal Cancer
At Envita Medical Centers, we find that majority of our patients were on the wrong drug targets before coming to us
and
in our clinical experience, nearly all patients are missing vitally important targets to their cancer treatment. When
targeting is missed due to the absence of detailed genomic testing, patients lack actionable metastatic disease
information, which is needed to guide the treatment in real-time.
Many colon (colorectal) cancer patients perusing standard cancer treatment may have to undergo a colectomy, surgical
removal of colon, and have to use a colostomy bag to divert solid waste out of their body, but our treatments attack
your cancer while healing you holistically. At Envita, with our personalized precision options we aim to ensure that
surgical resections, if any, do not impact your quality of life, as we work towards increasing longevity and reducing
toxicity in your body, just like in Sandy’s case.
Sandy was given only 20% - 30% chance of survival beyond
a year, despite going through standard NCCN guideline treatments.
However, with Envita's precision technology, she defied
these statistics and has been leading a healthy and cancer free life for over two decades.
A genetic disease like cancer needs personalized treatment because genetics vary from person to person. We offer
personalized genetically targeted treatment in a unique N of 1 model,
enabling
us to modify treatment based on individual patient responses. Our four-pillared approach to customize your treatment
at
every level helps in striking at the core of the disease, pushing you closer towards a long-term remission.
At Envita, we perform an extensive genomic identification to understand the root cause of each patient’s
cancer
expressions, irrespective of their colon cancer stages. This detailed testing helps us analyze many more
mutations,
beyond epidermal growth factor receptor (EGFR), neurotrophic tropomyosin receptor kinases (NTRK),
microsatellite
instability (MSI), BRAF, and RAS family of genes. According to the National Cancer Institute, 45% of
colorectal cancers are driven by the RAS family of genes.
Identifying each of these mutations helps in better understanding of
patient-specific biomarkers, which in turn enhances
precision treatment options. These proprietary genetic tests guide us to appropriate drug targets with the
highest
potential of response to care.
At Envita, we understand that approximately 5 percent of all colon cancers may be the result of mutations due to
inherited causes, leaving the remaining 95 percent to other factors such as diet, environment, heavy metal exposure,
chemical toxins, and infections [6]. Findings from extensive epidemiological and experimental investigation have
linked
consumption of several foods and nutrients to the risk of colorectal neoplasia [7].
All these factors may trigger genetic mutations, which can evade the immune system, leading to the growth of cancer.
Decoding the cause and the specific genetic mutations, in each individual patient is a crucial step to treating this
genetic disease.
Step 2
Immuno Targeting Trains Your Body to Attack the Cancer
At Envita, we use the Ultra Analytes Liquid Biopsy to examine genetic mutations and establish actionable chemo
and
immunotherapy targets. These targets are deciphered from a detailed analysis of the Circulating Tumor Cells
(CTCs) in a
patient’s blood sample. CTCs are small particles which break away from a growing polyp or tumor and enter the
patient’s
blood stream, carrying the cancer in micro metastatic forms to other parts of the body.
There are many advantages of analyzing the CTCs via liquid biopsy, over the standard healthcare
approach involving
invasive tumor biopsies. Most hospitals do a tissue biopsy during initial cancer diagnosis and basing your treatment
on
this biopsy may not be effective, because the fast-mutating cancer cells can change biomarker information quickly. On
the contrary, investigating the CTCs enables our treatment to constantly evolve and stay ahead of the mutations,
allowing even late-stage patients like Sandy to respond to care and recover holistically. In early-stage cancer cases,
the liquid biopsy helps to identify and proactively treat sites of metastasis, even before the cancer manifests itself
in distant parts.
Advanced Immunotherapy for Colon Cancer
Our personalized treatment protocols increase the mechanisms of action against each patient’s specific cancer by
including customized immunotherapy options. Immunotherapy utilizes genetic information to assist the immune system in
finding and killing cancerous cells. Our body is naturally adapted at killing thousands of cancerous and precancerous
cells daily, but this ability may get impacted when your immune system is not performing optimally.
Standard healthcare treatments, such as maximum dose chemotherapy regimens, radiation therapy, and surgery may
negatively impact patients’ immune systems. In certain cases, the extent of the impact is detrimental enough to
severely
depress the immune system, allowing the cancer to continue its spread. At Envita, we harness the power of
immunotherapy
to check this growth and proliferation.
With the advent of smart drugs, immunotherapy has become an integral part of colorectal cancer treatment.
However, our
immunotherapies go beyond the scope of smart drugs or checkpoint inhibitors available on the market, as we
customize
different therapies and drugs to optimize treatment efficacy for each individual patient.
Patients may not respond to prescribed smart drugs for colon (colorectal) cancer, if their immune system is
acutely
poor, which is why we empower their immune system cells, in particular the NK (natural killer) and dendritic
cells. A
reactivated immune system is then capable of executing the desired impact of the smart drugs and check disease
proliferation.
Personalized Drug Design Enhances Treatment Efficacy
At Envita Medical Centers, we take personalization to the next level by designing patient-specific drugs to
attack
cancerous cells and improve overall gastrointestinal health. In our clinical opinion, a powerful combination
of FDA
approved drugs, repurposed drugs, and custom-compounded adjuvants improves your chances of overcoming the
disease.
FDA Approved Drugs
Optimized for your cancer mutations.
Repurposed Drugs
Off-label use of approved medications
Custom Compounded Adjuvants
Genetically typed for each patient.
We take the guesswork out of your colorectal cancer treatment as our detailed testing reveals your specific
biomarkers,
which guide us to the FDA approved and repurposed drugs with the highest potential of impacting your cancer. We even
adjust the doses of each of these drugs to suit the needs of the patient. Every patient metabolizes differently,
making
dosage adjustment critical to optimize medicine benefits and reduce its toxicity.
However, the FDA approved and repurposed drugs available on the market may not be effective against all the
biomarkers,
revealed through our exhaustive testing. To fill this gap, we custom compound adjuvants at our in-house pharmacy,
which
may help in debulking the tumor while strengthening your immune system.
Our custom compounded adjuvants include advanced phytotherapeutics, comprising plant extracts and herbs, which may
prove
to be most effective against each patient’s unique biomarkers. They may be used either as neoadjuvants (deployed
before
systemic therapies), adjuvant therapy (follow-up to systemic therapies), or as part of our proprietary systemic
therapies as well.
Envita’s medicine combinations may be effective against unresectable cancers as they can cut off blood supply to
tumors
by impacting the production of vascular endothelial growth factor (vegf), a signal protein which stimulates the
formation of blood vessels around tumors.
Step 4
Precision Deployment Offers New Treatments with Fewer Side Effects
We bring the benefits of new treatments from around the world to our patients, as we aim to reduce side effects
and
avoid invasive surgeries with our precision deployment. Polyps or tumors that cannot be removed via colonoscopy
may be
deactivated through our proprietary interventional radiology procedures, which kill the cancerous cells with
minimal
side effects.
Our proprietary methods of precision deployment increase the bio absorption of anti-cancer medicines and reduce
their
side effects. In certain cases, the side effects can be severe enough to demotivate patients from continuing
treatment,
which is what Sandy experienced with her one-size-fits-all conventional treatment.
To counter such challenges, at Envita we use intravenous or interventional radiology procedures, which
administer the
chemo and immuno agents directly at the cancer site, minimizing chances of damaging surrounding healthy cells.
Depending
on each patient’s biomarkers and the site and size of their colorectal polyps or tumors, our doctors decide on
any one
or a combination of precision deployment mechanisms to attack their cancer, while healing them holistically.
At Envita, we treat our patients like family while offering them all aspects of palliative care during
treatment, as
described by the American Cancer Society, except transitioning to hospice care because we do not take in
patients if we
cannot make a difference to their lives. We do a free medical records review for all patients before we decide
to take
them in for treatment. In fact, we have treated several patients who were sent to hospice care by conventional
cancer
treatment centers and today they are leading a healthy, disease-free life.
GTFC™ (Genetically Targeted Fractionated Chemotherapy), determines patient-specific chemotherapy options based
on
genetic
testing and not primary cancer site alone. Cancers are caused by mutations occurring within cells, therefore
selecting
treatments based on genetic mutations can provide advantages that may have gone overlooked [8].
The knowledge of which chemotherapies and natural agents are likely to be most effective against each patient’s
specific
colorectal cancer biomarkers, allows us to utilize metronomic dosing, often 1/10 of the dose patients receive at
regular
cancer clinics. The low dose of chemotherapy enables us to use multiple targeted agents at once, with far less
side
effects as compared to maximum dose chemotherapy.
Many of our patients complain that the chemotherapies they received at their previous clinics were worse than
the
symptoms of cancer itself. At Envita, fewer side effects help our patients to sail through the treatment
smoothly, as
their immune system’s ability to check cancer growth and spread is improved through the treatment process.
Envita's GTFC™ vs. Standard Chemotherapy
Envita Medical Centers
Standard Chemotherapy
Helps to improve chemotherapy delivery to the tumor using a "Trojan Horse" delivery mechanism.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
Uses genetic molecular profiling to understand all the facets of each patient's specific cancer.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
Uses targeted treatment to enhance the mechanism of cancer kill.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
Uses microdosed (fractionated) chemotherapies, reducing the chances of impacting healthy cells.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
Minimizes toxicity to normal cells, lowering the chance of side-effects related to administration.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
Uses patient-specific supportive immunotherapy to strengthen the immune system.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
Aims to reduce multidrug resistance by administering 10 - 20% of the medication delivered in maximum dose
chemo.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
Allows custom-compounded medications to be readministered in tandem to suit each patient's individual cancer
mutations.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
*Individual results may vary. Envita
makes no guarantees for outcomes.
In certain cases of advanced colorectal cancer, patients may develop liver tumors, renal carcinomas, or tumors
in other
parts of the body as the cancer metastasizes. To treat these sites of metastases, we use CIPI™ (Chemo Immuno
Precision
Injections), a unique form of tumor chemoembolization for shutting off inoperable tumors that are fibrous and
difficult
to penetrate through traditional intravenous chemotherapy methods. This interventional radiology procedure has
the
potential to revolutionize the treatment of late-stage colorectal cancers by targeting large tumor sites of
cancer
metastasis.
With CIPI™, genetically personalized micro-dosed medications are directly injected into the tumor via a tiny
catheter,
thinner than a strand of hair. These medications deactivate the tumors, which then emit antigens, training your
immune
system to identify and kill cancer cells elsewhere in the body. This reactivated ability of the immune system helps
in
reducing chances of metastasis, stacking the odds in favor of the colon (colorectal) cancer patients.
Envita's CIPI™ vs. Standard Surgery
Envita Medical Centers
Standard Surgery
Minimally invasive so it can be performed within 40-50 minutes, without the need for large surgical
incisions.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
Can be performed multiple times, even at close intervals, because there is minimal risk of post-op
complications.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
No need for general anesthesia, reducing the health risks that can result from being put into a
medically induced coma to perform an invasive surgery.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
Faster recovery time as compared to traditional surgery, due to the minimally invasive administration.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
Provides direct tumor targeting, which delivers patient-specific genomic agents into the tumor.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
Causes a systemic immune response where the immune system is reactivated to find and attack other
metastatic cancer sites in the body.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
Performed by highly trained medical professionals in an outpatient setting, so there is no need of
hospital stays for recovery.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
*Individual results may vary. Envita
makes no guarantees for outcomes.
Colorectal cancers (includes colon and rectal cancers) are the most common cancers of the gastrointestinal tract, and
they are categorized depending on the type of cells of disease origin. They are sub-divided as follows:
Adenocarcinomas
Carcinoid tumors
Gastrointestinal stromal tumors
Lymphomas
Sarcomas
Some of the less common cancers of the gastrointestinal tracts are:
Intestinal cancers called the small intestine cancer or small bowel cancer
Anal cancer
Call Us Today
At Envita, we have several options for our patients through multifaceted integrated treatment protocols, aiming
towards
their holistic recovery. Our medical experts, including oncologists, interventional radiologists, researchers, and
pharmacists, undergo over 1,500 hours of training to adapt to our unique personalized precision oncology options. If
you
or a loved one has any questions regarding colon cancer or any other cancer, please contact us at: 866-830-4576. May
God
bless you on your journey to healing.
[1] Zare-Bandamiri M, Fararouei M, Zohourinia S, Daneshi N, Dianatinasab M. Risk Factors Predicting Colorectal
Cancer
Recurrence Following Initial Treatment: A 5-year Cohort Study. Asian Pac J Cancer Prev. 2017;18(9):2465-2470.
Published
2017 Sep 27. doi:10.22034/APJCP.2017.18.9.2465
[2] Hu Z, Ding J, Ma Z, et al. Quantitative evidence for early metastatic seeding in colorectal cancer. Nat
Genet.
2019;51(7):1113-1122. doi:10.1038/s41588-019-0423-x
[3] Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin
Colon
Rectal Surg. 2009;22(4):191-197. doi:10.1055/s-0029-1242458
[4] Precision Oncology News, Survey of Precision Oncology Programs Shows Continued Adoption, Though 'Success'
Metrics
Unclear Nov 04, 2020
[5] Hu T, Li Z, Gao CY, Cho CH. Mechanisms of drug resistance in colon cancer and its therapeutic strategies.
World J
Gastroenterol. 2016;22(30):6876-6889. doi:10.3748/wjg.v22.i30.6876
[7] Song M, Garrett WS, Chan AT. Nutrients, foods, and colorectal cancer prevention. Gastroenterology.
2015;148(6):1244-60.e16. doi:10.1053/j.gastro.2014.12.035
[8] Smith, A. , Oertle, J. and Prato, D. (2015) Genetically Targeted Fractionated Chemotherapy. Journal of Cancer
Therapy,
6, 182-198. doi: 10.4236/jct.2015.62021.
Choose Envita Medical Centers
Our team is ready to help you get your life back! Please enter your contact information and a Patient Care
Expert will contact you shortly. If you would rather speak now, please give us a call at 1-866-830-4576.
